About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
After a more lenient insulin protocol was implemented at the authors’ institution, patients’ blood glucose values stayed within the target range for a shorter time than with the former (stricter) protocol. Fewer episodes of hypoglycemia occurred with the newer protocol, but rates of severe hypoglycemia were similar with both protocols.
Katerina I. Petrov, PharmD; Tammy L. Burns, PharmD, BCPS; and Andjela Drincic, MD
Drug Use Evaluation of Moxifloxacin (Avelox) Using a Hand-Held Electronic Device At a Canadian Teaching Hospital
Seeking to determine whether moxifloxacin was being overused as a first-line therapy in the hospital, the authors found a high rate of appropriate use. Personal digital assistants (PDAs) were helpful, easy to use, and superior to paper methods in collecting data for their DUE review.
Jennifer A. E. Samilski, MD; Tim T. Y. Lau, PharmD, ACPR; Dean H. T. Elbe, PharmD, ACPR, BCPP; Amneet K. Aulakh, PharmD, ACPR; and Eric M. C. Lun, PharmD, ACPR
More Power—but More Burdens—for Pharmacists and Pharmacies
The FDA is debating whether to switch more prescription drugs to a new over-the-counter category and whether a drug could be classified as both a prescription and a nonprescription product. If the FDA approves this paradigm, pharmacists and pharmacies would have important roles to play.
Topics include immediate-use glucose, insulin, and potassium for cardiac protection; vorapaxar to prevent atherothrombosis; and rivaroxaban for the treatment of pulmonary embolism. Interactions with dietary supplements are also reviewed.
Implementing policies for pharmaceutical sales representatives who visit hospitals
Matthew Grissinger, RPh, FASCP
Benefits and shortcomings of a national identification system for tracking medical devices
FDA approvals, drug indications, and updates
Axitinib (Inlyta) for renal cell carcinoma; tafluprost (Zioptan) to reduce intraocular pressure; and lucinactant (Surfaxin) to prevent respiratory distress syndrome in premature infants
Marvin M. Goldenberg, PhD, RPh, MS
Fidaxomicin (Dificid), a Novel Oral Macrocyclic Antibacterial Agent For the Treatment of Clostridium difficile–Associated Diarrhea in Adults
Fidaxomicin (Dificid) for Clostridium difficile–associated diarrhea
Martin Paspe Cruz, PharmD, CGP, BCPP